Neurocrine Biosciences Inc (NBIX) Income Statement

An income statement shows a company's revenue, expenses, and profit over a reporting period.

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally.

Total Revenue Chart for Neurocrine Biosciences Inc

Neurocrine Biosciences Inc (NBIX) revenue for FY2025 was USD 2.9B, a 21.4% change from FY2024. Neurocrine Biosciences Inc's revenue grew from USD 19.2M in 1996 to USD 2.9B in 2025 (14798.4% over 29 years). Earnings per share grew from USD 0.67 in 2011 to USD 1.56 in 2022 (134.3%). Revenue compound annual growth rate: 5-year CAGR of 22.3%, 10-year CAGR of 64.5%, 20-year CAGR of 17.0%.

The most recent 8 years are real; the rest is blurred as a preview. Sign up free to unlock every line item, quarterly data, and the real full history. Free account: 8 years of history for 10 flagship companies. Premium: full history for 500+ companies. Premium is €10.00/month. See pricing.

Total Revenue (US Dollars)

R&D as % of Revenue

Key Stats

Market Cap
$14.79B
Implied Share Price
$145.51
Enterprise Value
$14.42B
Revenue (TTM)
$3.37B
EBITDA
$913.30M
Profit Margin
20.91%
Trailing P/E
21.15
Forward P/E
14.12
Price/Book (MRQ)
3.90
Price/Sales (TTM)
4.38
EV/EBITDA
15.65
EV/Revenue
4.28
Dividend Yield
—
Book Value
$36.35
Free Cash Flow (FY2025)
$748.70M
Free Cash Flow Yield
5.06%

Snapshot as of 6th October 2026 — not point-in-time controlled, may lag the live market by a few days.